NXL
Nexalin Technology, Inc.
Key Financials
Operating Income
$-8390881
↓ 8.2%
Revenue
$301647
↑ 78.8%
Gross Profit
$240274
↑ 81.8%
Net Income
$-8222181
↓ 8.1%
EPS (Diluted)
$-0.50
↑ 39.8%
Total Assets
$4.6M
↑ 9.8%
Total Liabilities
$887333.00
↑ 62.3%
Cash & Equivalents
$654783.00
↑ 14.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 8/17/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 8-K | 7/29/2026 | View on SEC |
| 8-K | 7/27/2026 | View on SEC |
| ARS | 7/10/2026 | View on SEC |
| DEF 14A | 7/10/2026 | View on SEC |
| PRE 14A | 6/29/2026 | View on SEC |
| 8-K | 6/17/2026 | View on SEC |
| 8-K | 5/19/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NXL |
| Company Name | Nexalin Technology, Inc. |
| CIK | 1527352 |
| Sector | Electromedical & Electrotherapeutic Apparatus |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 3845 |
| SIC Description | Electromedical & Electrotherapeutic Apparatus |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (832) 260-0222 |